8 Gene Editing Applications Moving from Lab to Clinical Use

5. Duchenne Muscular Dystrophy - Restoring Muscle Function

Duchenne Muscular Dystrophy (DMD), a devastating X-linked genetic disorder affecting approximately 1 in 3,500 male births, represents one of the most challenging targets for gene editing due to the large size of the dystrophin gene and the systemic nature of muscle involvement throughout the body. This progressive muscle-wasting disease is caused by mutations in the dystrophin gene that result in absent or non-functional dystrophin protein, leading to muscle fiber damage, weakness, and ultimately respiratory and cardiac failure. Gene editing approaches for DMD focus on restoring dystrophin expression through various strategies, including exon skipping to restore the reading frame, direct correction of point mutations, or insertion of functional mini-dystrophin genes. The complexity of treating DMD lies in the need to deliver gene editing tools to muscles throughout the body, including the heart and diaphragm, which are critical for survival. Researchers are exploring multiple delivery methods, including adeno-associated virus (AAV) vectors and lipid nanoparticles, to achieve widespread muscle targeting. Clinical trials led by companies like Solid Biosciences and Sarepta Therapeutics are investigating systemic delivery of gene editing components, with early results showing promise in restoring dystrophin expression in muscle biopsies. The challenge extends beyond just correcting the genetic defect to ensuring that the restored dystrophin protein is produced at sufficient levels and in the right locations to meaningfully improve muscle function. Success in DMD gene editing would not only provide hope for affected patients and families but also establish important precedents for treating other systemic genetic disorders that require body-wide gene correction.